Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE versus XYLOCAINE DENTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE versus XYLOCAINE DENTAL.
ALPHACAINE HYDROCHLORIDE vs XYLOCAINE DENTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking the initiation and conduction of nerve impulses.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Xylocaine Dental (lidocaine HCl 2% with epinephrine 1:100,000 or 1:50,000): For infiltration/inferior alveolar nerve block, maximum dose 3.4 mg/kg (4.5 mg/kg with epinephrine 1:100,000) not to exceed 300 mg; usual adult dose: 1–5 mL (20–100 mg) administered via oral submucosal injection.
None Documented
None Documented
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
1.5–2 hours in adults with normal hepatic function. Prolonged to 2–3 hours in patients with hepatic impairment or congestive heart failure; may exceed 5 hours in severe hepatic disease.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Renal excretion of unchanged drug and metabolites accounts for >95% of the dose. Approximately 70% is excreted as the metabolite 4-hydroxy-2,6-xylidine; less than 10% is unchanged lidocaine. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic